Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...

Molecular Degrader of Extracellular Proteins Platform: Biohaven’s (BHVN) novel immune-modulating extracellular degrader platform harnesses selectivity, rapidity, and patient-friendly self ...

Get Our Latest Research Report on Biohaven Biohaven Price Performance Biohaven stock opened at $38.30 on Friday. The firm’s 50-day moving average is $39.65 and its two-hundred day moving average ...

$60,000 of BIOHAVEN PHARMACEUTICALS INC. lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Policies related to drug ...

Merus has announced a research collaboration and license agreement with Biohaven. Under the agreement, Biohaven and Merus will to co-develop three antibody-based therapies. NOW OPEN: 200 Charter ...

Several other brokerages have also recently commented on BHVN. TD Cowen upped their target price on Biohaven from $55.00 to $75.00 and gave the company a “buy” rating in a report on Wednesday ...

Under the terms of the agreement, Biohaven is responsible for the preclinical ADC generation of three Merus bispecific antibodies under mutually agreed research plans. The agreement includes two ...

(RTTNews) - Biohaven Ltd. (BHVN) and Merus N.V. (MRUS) announced a research collaboration and licensing agreement aimed at co-developing three innovative bispecific antibody drug conjugates (ADCs).

Biohaven presented positive news regarding its portfolio during its presentation at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13. In a press release, the company’s CEO Vlad ...